Stevenage, United Kingdom

Andrew Richard Whittington

USPTO Granted Patents = 2 


Average Co-Inventor Count = 7.9

ph-index = 1

Forward Citations = 24(Granted Patents)


Location History:

  • Greenford, GB (1994)
  • Stevenage, GB (2009)

Company Filing History:


Years Active: 1994-2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Andrew Richard Whittington - Innovator in Pharmaceutical Patents**

Introduction

Andrew Richard Whittington is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceuticals, holding two patents that showcase his innovative spirit and dedication to improving healthcare.

Latest Patents

Whittington's latest patents include "Pyrimidine derivatives and their use as CB2 modulators," which relates to novel pyrimidine derivatives and their pharmaceutical applications, particularly in treating diseases associated with the cannabinoid receptor. His other patent, "Medical use for tachykinin antagonists," focuses on the use of tachykinin antagonists, including substance P antagonists, for treating emesis. This patent describes novel tachykinin antagonists and the processes for their preparation.

Career Highlights

Andrew Whittington is affiliated with Glaxo Group Limited, where he continues to drive forward research and development in innovative pharmaceutical solutions. His work has profoundly impacted medical treatments related to pain management and nausea.

Collaborations

Throughout his career, Whittington has collaborated with esteemed colleagues, including Alan Naylor and Russell Michael Hagan. These partnerships have played a crucial role in advancing the research and practical applications of his patented inventions.

Conclusion

Andrew Richard Whittington stands out in the realm of innovation, particularly in pharmaceuticals, through his groundbreaking patents. His contributions not only support the advancement of medical treatments but also reflect the collaborative spirit of research and innovation in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…